Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: Clinical efficacy and correlative analyses.
Publication/Presentation Date
2-23-2023
Abstract
Malignancies can become reliant on glutamine as an alternative energy source and as a facilitator of aberrant DNA methylation, thus implicating glutaminase (GLS) as a potential therapeutic target. We demonstrate preclinical synergy of telaglenastat (CB-839), a selective GLS inhibitor, when combined with azacytidine (AZA),
ISSN
2693-5015
Published In/Presented At
Konopleva, M., DiNardo, C., Bhagat, T., Baran, N., Lodi, A., Saxena, K., Cai, T., Su, X., Skwarska, A., Guerra, V., Kuruvilla, V., Konoplev, S., Gordon-Mitchell, S., Pradhan, K., Aluri, S., Collins, M., Sweeney, S., Busquet, J., Rathore, A., Deng, Q., … Verma, A. (2023). Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: Clinical efficacy and correlative analyses. Research square, rs.3.rs-2518774. https://doi.org/10.21203/rs.3.rs-2518774/v1
Disciplines
Medicine and Health Sciences
PubMedID
36865338
Department(s)
Department of Pathology and Laboratory Medicine
Document Type
Article